INTRODUCTION

BCL2-interacting killer (BIK) protein activates the mitochondrial apoptotic pathway by inducing Ca
2+ release from the endoplasmic reticulum (ER) and the remodeling of the mitochondrial cristae that releases cytochrome c and activates caspase 9 (Chinnadurai et al., 2008; Germain et al., 2002) . BIK is a tumor suppressor, a prognostic marker, and a therapeutic target for cancers, and BIK expression is induced by DNA damage, viral infection, and cytokines (Chinnadurai et al., 2008) . BIK expression inhibits antiapoptotic effects of oncoproteins and viral infection and induces cell apoptosis (Han et al., 1996) . In contrast, loss of BIK per se fails to alter apoptotic profile in hematopoietic and endothelial cells, while combined deficiency of BIK and BIM (another BH3-only protein) exhibits additive effect on apoptosis in germ cells (Coultas et al., 2005) , indicating a critical yet redundant role of BIK. The cellular levels of BIK are controlled by both posttranslational and transcriptional mechanisms (Hur et al., 2006; Marshansky et al., 2001 ). However, these regulatory mechanisms for BIK expression and the signaling pathways mediating these steps are not well defined. Protein kinase C (PKC) isoforms are key regulators of apoptosis (Brodie and Blumberg, 2003; Reyland, 2007) and PKCd, a novel PKC subfamily member, is required for apoptosis in response to several stimuli (Brodie and Blumberg, 2003) , including DNA damage (Yoshida, 2007) . Mice deficient in PKCd are resistant to g-irradiation-induced apoptosis (Humphries et al., 2006) . DNA damage-induced p53 activation and protein levels are similar in primary cells derived from PKCd +/+ and PKCd À/À mice, indicating that PKCd functions downstream of the DNA damage response (Humphries et al., 2006) . PKCd regulates the mitochondrial apoptosis pathway (Humphries et al., 2006; Steinberg, 2004) and this requires nuclear targeting of PKCd (Yoshida, 2007) . PKCd is targeted to different cellular compartments, depending on its phosphorylation status (Rybin et al., 2004) . Phosphorylation of tyrosines 64 and 187 on PKCd appears important for PKCd's role in apoptosis induced by DNA damage (Blass et al., 2002) . However, tyrosine phosphorylation only serves to amplify the later stages of the apoptosis signal and is not required for the nuclear targeting of full-length PKCd (Blass et al., 2002) . After initiation of apoptosis, PKCd is cleaved by caspase or other proteases into regulatory and catalytic domains, and these further activate downstream signaling cascades (DeVries et al., 2002) . The cleaved catalytic fragment of PKCd is important for the progression of apoptosis (Ghayur et al., 1996) , and the regulatory fragment is required for the optimal function of PKCd (Blass et al., 2002) .
Activated PKCd could also induce apoptosis without being proteolytically cleaved by caspase (Tanaka et al., 2003) . It was proposed that the catalytic fragment and the full-length PKCd target different nuclear substrates at different stages of apoptosis (Steinberg, 2004) . There are substrates for nuclear PKCd activity, but it is not clear which of these are critical for induction of apoptosis. PKC isoforms are regulated by phosphoinositide signaling through generation of diacylglycerol by cleavage of phosphatidylinositol-4,5-bisphosphate (PI4,5P 2 ), and some PKCs directly interact with and are regulated by PI4,5P 2 (Chauhan and Brockerhoff, 1988; Huang and Huang, 1991; Lee and Bell, 1991) . The role of phosphoinositides in the modulation of nuclear PKCd is not defined.
In nuclei, there is a distinct phosphatidylinositol cycle that is independent of the cytosolic pathway (Barlow et al., 2010; Cocco et al., 1987) . Nuclear diacylglycerol kinase theta (DGKq), phospholipase C beta 1 (PLCb1), PI4,5P 2 , and phosphatidylinositol-4-phosphate 5-kinase I alpha (PIPKIa) all were detected and targeted to nuclear speckles (Gonzales and Anderson, 2006; Tabellini et al., 2003) . These findings suggest a mechanism where nuclear signals emanating from PI4,5P 2 may regulate nuclear localized PKC isoforms.
Recently gene expression has been shown to be directly regulated by nuclear phosphoinositide signaling through a noncanonical poly(A) polymerase, speckle-targeted PIPKIaregulated poly(A) polymerase (Star-PAP) . Star-PAP controls the expression of a subset of genes by assembling into a distinct 3 0 end cleavage and polyadenylation complex on its target mRNAs. Star-PAP associates with regulatory proteins such as PIPKIa and casein kinase I (CKI) isoforms a and ε, which are required for 3 0 end processing Laishram et al., 2011; Mellman et al., 2008) . PI4,5P 2 directly and specifically controls the activity of Star-PAP . Star-PAP has been proposed to function as a signal-regulated effector of mRNA 3 0 end processing that may integrate into different pathways (Barlow et al., 2010) . In this study, we identified BIK as a direct target of Star-PAP and defined a Star-PAP-specific binding region on the BIK mRNA. Upon DNA damage signaling, Star-PAP, PKCd, and PIPKIa form a functional complex required for BIK expression in response to the apoptotic signal induced by etoposide. These data define Star-PAP as a molecular target for nuclear PKCd that controls the expression of BIK, an important switch in the mitochondrial apoptosis pathway.
RESULTS
Star-PAP and Associated PIPKIa Are Required for BIK Expression Cellular BIK is increased in response to DNA damage signaling (Fu et al., 2007) . Gene microarray analysis of Star-PAP knockdown cells implicated BIK as a Star-PAP target . To determine the role of Star-PAP in BIK expression, the mRNA and the protein levels of BIK were analyzed in the absence or presence of etoposide treatment. Etoposide (VP-16) is a DNA-damaging compound that inhibits topoisomerase II and induces apoptosis (Baldwin and Osheroff, 2005) . The optimal time used for etoposide treatment was determined by time-course experiments. In the DNA fragmentation analysis, DNA condensation was initiated at 4 hr post etoposide treatment ( Figure S1A ). Concomitantly, BIK protein levels were substantially increased during this time ( Figure S1B ). Therefore, this time after etoposide treatment was chosen for most of the experiments, except for the DNA laddering and the caspase 3/7 activity assays as described below.
Star-PAP control of BIK expression was measured by quantitative RT-PCR after Star-PAP knockdown by RNA interference (RNAi). BIK mRNA level decreased 8-fold after Star-PAP knockdown, proportional to the efficiency of Star-PAP knockdown ( Figure 1A ). The etoposide-potentiated BIK expression was reduced to the same extent ( Figure 1A) . Similarly, when PIPKIa was knocked down, both the basal and the etoposide-induced BIK expression were decreased ( Figures 1A and S1D) . Remarkably, while etoposide enhanced the cellular BIK protein content, knockdown of Star-PAP or PIPKIa diminished the BIK protein greater than 15-fold in both etoposide treated and nontreated cells ( Figures 1A and S1D ). Simultaneous knockdown of both Star-PAP and PIPKIa did not significantly enhance the block of BIK mRNA or protein expression ( Figure 1A ), indicating that Star-PAP and PIPKIa act in the same pathway for BIK expression.
Since Star-PAP is a poly(A) polymerase, we investigated the 3 0 end processing and polyadenylation of BIK pre-mRNA using 3 0 RACE assays with cDNA synthesized from total RNA isolated from cells after RNAi knockdown of Star-PAP or PIPKIa and etoposide treatment. Distinct RACE products for BIK were observed with the control cell mRNAs and an increase was noted after stimulation with etoposide ( Figures 1B and S1D ). There was a loss of RACE products upon Star-PAP or PIPKIa knockdown regardless of etoposide treatment (Figures 1B and S1D) . Ectopic re-expression of the wild-type (wt) but not the polymerase dead (pd) Star-PAP or the kinase dead (kd) PIPKIa, with silencing mutations (sm) that are resistant to the RNAi, rescued the loss of BIK in Star-PAP or PIPKIa knockdown cells ( Figures 1B and S1D ). The changes in BIK protein levels followed the similar pattern ( Figures 1B and S1D ). The Star-PAP nontarget mRNA, glyceraldehyde 3-phosphate dehydrogenase (GAPDH), was not affected by knockdown of Star-PAP/PIPKIa nor by stimulation with etoposide ( Figures 1B and S1D ). These data demonstrate that the Star-PAP poly(A) polymerase activity and the ability of PIPKIa to generate PIP 2 are required for BIK expression.
Consistent with the Star-PAP role in the cleavage of its target HO-1 pre-mRNA Mellman et al., 2008) , Star-PAP or PIPKIa knockdown resulted in an accumulation of uncleaved BIK pre-mRNA ( Figures 1B and S1D ). However, DNA damage stimulation reduced the uncleaved BIK message compared to the unstimulated control (Figures 1B and S1D (Figure 2A ). PMA activates a number of kinases, including PKC isoforms (Brose and Rosenmund, 2002) . Therefore the association of members of the PKC family with Star-PAP was analyzed by immunoblotting (IB). This identified PKCd but not PKCa (Figure 2B ) or any other PKC isoforms (data not shown) in the affinity purified Star-PAP complex under these conditions. The association of PKCd with Star-PAP was further confirmed by immunoprecipitation (IP) and IB of endogenous Star-PAP and PKCd ( Figure 2C ). However, the GST-tagged PKCd failed to pull down the His-tagged Star-PAP in vitro, indicating that the association of PKCd with Star-PAP is indirect (data not shown).
Star-PAP and the associated PIPKIa are spatially targeted to nuclear speckles in the cells . Our data demonstrate that PKCd was also targeted to foci that partially colocalized with Star-PAP ( Figure 2D , first four panels) and with the speckle marker SC-35 ( Figure 2D , middle and last four panels) as shown by immunofluorescence microscopy (IF).
Since PKCd is a component of the Star-PAP complex and may phosphorylate Star-PAP, the effect of exogenous PKCd kinase activity toward Star-PAP was analyzed. Recombinant PKCd phosphorylated the purified Star-PAP complex in a dosedependent fashion, and PMA treatment further enhanced PKCd-dependent phosphorylation of Star-PAP ( Figure 2E ). Consistently, PKCd phosphorylated the recombinant His-tagged Star-PAP ( Figure 2F ), indicating that Star-PAP is a direct substrate of PKCd. In both cases, IP of Star-PAP under denaturing conditions demonstrated that the 120 kDa 32 P-phosphorylated band was indeed Star-PAP ( Figures 2E and 2F , lower panels).
PKCd Directly Interacts with PIPKIa, and PI4,5P 2 Stimulated PKCd Kinase Activity toward Star-PAP PIPKIa and PKCd are components of Star-PAP complex. It is reported that some PKC isoforms interact with and are regulated by PI4,5P 2 (Chauhan and Brockerhoff, 1988; Huang and Huang, 1991; Lee and Bell, 1991) . We hypothesized that PI4,5P 2 could be a direct regulator of PKCd. As PIP kinases often define PI4,5P 2 signaling specificity by interacting with PI4,5P 2 effectors (Heck et al., 2007) , the interaction between PIPKIa and PKCd was investigated by in vitro GST pull-down assays. This demonstrated direct binding of PIPKIa to PKCd ( Figure 3A ). Moreover, endogenous PKCd was coimmunoprecipitated with PIPKIa and vice versa ( Figure 3B ), indicating that PKCd and PIPKIa associate in vivo. To determine if PKCd activity is regulated by PI4,5P 2 , PKCd kinase activity was assayed using myelin basic protein (MBP) as generic PKCd substrate in the presence of an increasing amount of PI4,5P 2 . PI4,5P 2 stimulated PKCd kinase activity toward MBP (Figure 3C ). Most importantly, PI4,5P 2 stimulated PKCd activity toward Star-PAP purified from cell lysates ( Figure 3D ). These data demonstrate that PIPKIa within the Star-PAP complex is required for the recruitment of and serves as a docking site for PKCd in vivo. This suggests that PIPKIa could be a substrate for PKCd or may directly modulate its activity. Recombinant PKCd failed to phosphorylate PIPKIa in vitro (data not shown). To determine if PIPKIa directly regulates PKCd activity, increasing PIPKIa was combined with PKCd, and kinase activity toward MBP or Star-PAP was assayed. Remarkably, PIPKIa inhibited PKCd activity toward Star-PAP ( Figure S3A ) and MBP (data not shown) in a dose-dependent fashion. The PIPKIa inhibition of PKCd activity was relieved by addition of PI4,5P 2 ( Figures 4D and S3B) , again indicating that PIPKIa activity and PI4,5P 2 production modulate PKCd activity. Surprisingly, PMA failed to stimulate PKCd activity toward recombinant Star-PAP when PKCd was associated with PIPKIa ( Figure S3C ). C and D) . Total proteins in the gels were stained with Coomassie blue. Star-PAP contents and specific phosphorylation in the reactions were evaluated by IP followed by phosphorimaging and IB (D bottom panels). This supports the idea that PI4,5P 2 is the primary lipid messenger for PKCd activation in this signaling pathway.
PKCd Regulates Star-PAP Activity, BIK Expression, and Is Associated with BIK mRNA BIK and PKCd both mediate the mitochondrial apoptosis pathway Humphries et al., 2006) . As Star-PAP controls BIK expression and the association of PKCd with Star-PAP is increased in response to DNA damage, the possibility that PKCd modulates BIK expression was explored. Knockdown of PKCd dramatically reduced both basal and etoposide-stimulated BIK mRNA and protein levels ( Figure 5A ), equivalently to Star-PAP and PIPKIa knockdown. Re-expression of the wild-type (wt) but not the kinase dead (kd) PKCd rescued the endogenous PKCd knockdown phenotype of BIK mRNA and protein loss ( Figure 5A ). The expression of kinase dead PKCd appeared to act as a dominant negative mutant, which blocked BIK expression ( Figure 5A ). This indicates that the interaction and kinase activity of PKCd are required for the regulation of Star-PAP.
As PKCd interacts with and phosphorylates Star-PAP, the role of PKCd in the 3 0 end processing of BIK mRNA was investigated by using 3 0 RACE assays. Knockdown of PKCd resulted in a loss of RACE product in control and DNA-damaged cells ( Figure 5A ), similarly to the knockdown of Star-PAP and PIPKIa ( Figures 1B and S1D ). This phenotype was rescued by the expression of PKCd wt/sm but not PKCd kd/sm ( Figure 5A ). Expression of PKCd kd/sm also decreased the RACE product similarly to PKCd knockdown ( Figure 5A ). The control GAPDH was not affected by knockdown or ectopic expression of PKCd or DNA damage ( Figure 5A ). However, knockdown of PKCd had no effect on the cleavage of BIK pre-mRNA in control cells, but increased the uncleaved message upon DNA damage ( Figure S4A ). While PKCd wt/sm overexpression rescued the cleavage defect, PKCd kd/sm failed to restore BIK pre-mRNA cleavage ( Figure S4A ). These data demonstrate that PKCd is required for the generation of mature BIK mRNA in vivo. Consistent with this role in BIK mRNA 3 0 end processing, PKCd and PIPKIa associate with the BIK UTR RNA along with Star-PAP, as shown by RNA immunoprecipitation (RIP) ( Figure 5B ). In contrast, PAPa was associated with the Star-PAP nontarget GCLC RNA, but not with BIK RNA. PIPKIa was also not associated with GCLC RNA, whereas PKCd showed weak association ( Figure 5B ), indicating that BIK mRNA is a selective target for the Star-PAP pre-mRNA processing complex.
To further explore whether PKCd directly modulates Star-PAP poly(A) polymerase activity, Star-PAP was affinity-purified from the cells stably expressing FLAG-Star-PAP with or without PKCd knockdown or/and etoposide treatment ( Figures S4B  and S4C ). The purified Star-PAP was used in the in vitro poly(A) polymerase assays as previously described . Upon DNA damage (etoposide treatment), the poly(A) polymerase activity of Star-PAP was stimulated and the addition of PI4,5P 2 further enhanced this activity ( Figure 5C ). Star-PAP poly(A) polymerase activity under these conditions was highly processive adding >600 adenine residues after initiation ( Figure S5B ). Nevertheless, Star-PAP has linear enzyme kinetics in its polyadenylation activity over this time range (data not shown). The PI4,5P 2 stimulation of Star-PAP activity also required priming by etoposide treatment (Figure 5C ). Remarkably, PKCd was required for Star-PAP activation, as knockdown of PKCd ( Figure S4B ) blocked both the DNA damage stimulation and the priming required for PI4,5P 2 stimulation of Star-PAP activity ( Figure 5C ). These results were confirmed by assaying at the varying concentrations of Star-PAP purified from cells that were ± PKCd RNAi in the presence or absence of etoposide treatment ( Figure S5A) . The combined data demonstrate that PKCd is required for Star-PAP activity toward BIK downstream of DNA damage stimulation.
Star-PAP Binds to the BIK 3 0 UTR RNA Star-PAP directly binds to its target HO-1 pre-mRNA in the UTR upstream of the poly(A) signal and recruits the cleavage and polyadenylation specificity factor (CPSF) 160 and 73 subunits . Since Star-PAP associated with the BIK mRNA in vivo, a direct interaction was explored. A fragment of BIK 3 0 UTR RNA (À145 to +120 with respect to cleavage site), containing the cis-regulatory elements and the equivalent Star-PAP regulatory region as identified in HO-1, and an RNA fragment from the equivalent region of the Star-PAP nontarget gene GCLC were transcribed. In vitro RNA electrophoretic mobility shift assays (EMSA) using radiolabeled BIK or GCLC UTR RNA were carried out. A slower migrating binary complex of Star-PAP and BIK RNA was detected with increasing Star-PAP concentration, but there was no detectable interaction with the GCLC RNA (Figure 6A ). This BIK RNA fragment was also confirmed as the minimum upstream sequence from the BIK cleavage site that show optimum binding to Star-PAP by deletion analysis of the BIK UTR (data not shown).
In competition experiments, the Star-PAP-BIK RNA complex was competed with 20-fold molar excess of cold BIK UTR RNA but not by a nonspecific RNA of similar length ( Figure 6B ). Addition of Star-PAP antibody but not a control antibody resulted in a supershift of the Star-PAP-BIK RNA complex ( Figure S6A ). PAPa did not bind to the BIK RNA at similar concentrations to that of Star-PAP (data not shown). These results are consistent with the RIP data ( Figure 5B ) and with previous reports that PAPa has low affinity for RNA (Wahle, 1991) , and they demonstrate that Star-PAP directly and specifically interacts with the 3 0 UTR of the BIK pre-mRNA.
To map the Star-PAP binding region on the BIK UTR, an RNA footprinting assay was employed using the BIK UTR RNA substrate used in EMSA experiments. A ladder of digested fragments of BIK RNA was generated with different concentrations of RNase S ( Figure 6C, lanes 5 and 6) . The site of protection by Star-PAP binding was obtained after comparing with that received His-Star-PAP ( Figure 6C, lanes 7 and 8) . Several positions within the BIK UTR were specifically protected by Star-PAP against RNase S cleavage. The protected region extended from $120 to $70 nucleotides upstream of the cleavage site (taken as +1) with a Star-PAP dose dependency for protection ( Figure 6C) . A similar result was also observed from footprinting with RNase T1 (Figure S6C ). The putative Star-PAP binding region on BIK UTR RNA was deleted and reassayed for binding using EMSA. The results showed that Star-PAP did not bind the BIK RNA lacking this region (Figure 6D ). These data defined the Star-PAP binding sequence in BIK UTR ( Figure 6E ).
The BIK UTR Sequence Suggests a Mechanism for Star-PAP Specificity
Comparison of the Star-PAP binding regions in BIK and HO-1 UTR showed similar nucleotide sequences with high GC contents (>65%) ( Figure S6B ). Using a bioinformatics approach, the UTR sequences of all genes that were downregulated by Star-PAP knockdown in the microarray analysis were analyzed. This demonstrated that there is an enrichment of G and C nucleotides upstream of cleavage site in the putative Star-PAP target mRNAs compared to the UTRs of Star-PAP nonregulated genes ( Figure 6F ). In addition, we observed enrichment of G-rich 4-mers (CUGG, GGGG, GGGA, GGAG, etc.) around the cleavage site of Star-PAP targets ( Figure 6G ). This is consistent with the Star-PAP footprint on HO-1 and BIK, and indicates that Star-PAP directly binds GCrich sequence upstream of the poly(A) signal.
Most interestingly, this analysis showed a deficiency in Ucontent 3 0 to cleavage site among the Star-PAP target genes, especially in the region of downstream sequence elements (DSE) ( Figure 6F ). This is important because CstF complex recognizes the U-rich or GU-rich DSE and cooperates with CPSF-160 binding to form a stable cleavage complex, required for canonical 3 0 end processing (Murthy and Manley, 1995; Zhao et al., 1999) . Our analysis also revealed that U-rich 4-mers (UUUU, UAUU, UUGU, etc.) were highly depleted in this region ( Figure 6G ) among the Star-PAP targets. Markedly, sequence analysis of the BIK UTR sequence demonstrated that in addition to the high GC-rich Star-PAP binding region upstream of the poly(A) signal, there was no U/GU-rich consensus or optimal DSE for CstF binding 3 0 to cleavage site ( Figure 6E ). This indicates that the deficiency of a CstF binding region might render the canonical PAPa-based 3 0 end processing complex unable to access BIK and potentially other Star-PAP target mRNAs. As Star-PAP functions distinctly by directly binding and recruiting the CPSF 160 and 73 subunits to the RNA , this may reduce the requirement for CstF binding.
Star-PAP Is Required for DNA Damage-Induced Apoptosis PKCd and BIK play key roles in apoptosis (Chinnadurai et al., 2008; Humphries et al., 2006; Reyland, 2007) . As nuclear PIPKIa and PKCd regulate Star-PAP-control of BIK mRNA processing and expression, Star-PAP may regulate the apoptotic response to DNA damage. To test this hypothesis, total genomic DNA was extracted from cells treated with or without Star-PAP knockdown or/and etoposide and assayed for DNA laddering indicative of chromatin DNA fragmentation. In non-etoposide-treated cells, basal DNA fragmentation level was observed and reduced in Star-PAP knockdown cells ( Figure 7A ). Etoposide induced DNA fragmentation and this was blocked by Star-PAP knockdown ( Figure 7A ). These results were corroborated by an analysis of caspase 9 and caspase 3/7 activation. DNA damage-induced cellular caspase 9 and caspase 3/7 activities were abolished by loss of Star-PAP ( Figure 7B ). It was reported that a requirement of BIK for apoptosis is likely cell-typedependent, and loss of another BH3-only protein BIM could impair the proapoptotic effect (Coultas et al., 2005) . To examine the combined effect of the loss of BIK expression via the Star-PAP-controlled pathway and the loss BIM expression, Star-PAP and/or BIM were knocked down followed by etoposide treatment and specific caspase activities were measured. While single knockdown of Star-PAP or BIM could each reduce caspase 9 and caspase 3/7 activities in etoposide-treated cells, double knockdown of Star-PAP and BIM further prevented the apoptotic effect ( Figure S7 ).
PKCd Regulation of the Star-PAP Specificity and Activity Is Specific for DNA Damage but Not Oxidative Stress Star-PAP regulates a subset of genes, including HO-1, that have roles in oxidative stress response Mellman et al., 2008) . PKCd is reported to play roles in aspects of the oxidative stress response (Konishi et al., 1997 ). Yet, there is no evidence for PKCd regulation of HO-1 expression. As PKCd regulates Star-PAP in the DNA damage-induced BIK expression pathway, we examined if PKCd is also required for oxidative stress-mediated Star-PAP regulation of BIK and HO-1 expression. While the oxidative stress agonist tBHQ induced dramatic increase in HO-1 protein level, the cellular BIK level remained unaffected ( Figure 7C, lanes 1 and 5) . As expected, Star-PAP or PIPKIa knockdown attenuated both HO-1 and BIK expression regardless of the presence of tBHQ ( Figure 7C, lanes 2, 3, 6, and 7 ). Yet, knockdown of PKCd diminished BIK but not HO-1 protein levels in both tBHQ nontreated and treated cells ( Figure 7C, lanes 1, 4, 5, and 8) .
Moreover, an in vitro poly(A) polymerase assay, using affinitypurified FLAG-Star-PAP from cells treated with or without PKCd knockdown in the presence or absence of tBHQ or etoposide treatment, showed that while PKCd knockdown blocked the etoposide priming of PI4,5P 2 -stimulation of Star-PAP activity ( Figure 7D, lanes 3, 4, 7 , and 8), tBHQ-and PI4,5P 2 -stimulated Star-PAP poly(A) polymerase activities were not impacted by the loss of PKCd ( Figure 7D, lanes 9, 10, 11, and 12 ). These data indicate that PKCd regulation of Star-PAP activity is specific to the DNA damage-signaling pathway where Star-PAP regulates BIK expression.
DISCUSSION
BIK expression is a key switch for the initiation of the mitochondrial apoptosis pathway. BIK is also recognized as a tumor suppressor (Chinnadurai et al., 2008) whose transcription is regulated in part by p53 (Hur et al., 2006; Mathai et al., 2002) and DNA damage stimuli (Real et al., 2006) . Although the mechanisms for BIK transcription have been studied, the role of BIK 3 0 end processing in its expression and translation remains uncharacterized. As BIK acts as an early initiator for apoptosis, the processing of the message is a fundamental step in the expression pathway.
Here, we have shown that Star-PAP controls the 3 0 end cleavage and polyadenylation of the BIK pre-mRNA, a process essential for stability, export, and translation of the message. Although BIK 3 0 UTR has an intact poly(A) signal (AAUAAA), it cannot be processed by the PAPa canonical 3 0 end processing complex. PAPa has very low affinity for RNA substrate (Martin and Keller, 1996; Wahle, 1991) and lacks RNA binding specificity (Zhao et al., 1999) . Thus, PAPa is recruited to pre-mRNA by the cooperative binding of CPSF to the poly(A) signal and CstF to a U/GU-rich element that is 3 0 to the cleavage site (Keller et al., 1991; Murthy and Manley, 1995) . There are examples of suboptimal poly(A) sequences, where an intact AAUAAA is not sufficient for the CPSF complex to bind the pre-mRNA and recruit PAPa (Gilmartin et al., 1995) . There are also examples of suboptimal CstF U/GU-rich element sites Maciolek and McNally, 2008; Tian et al., 2005) .
Star-PAP directly binds to the 3 0 end of pre-mRNAs upstream of the poly(A) signal (Figure 6 ). The Star-PAP protection region on both BIK and HO-1 shows a high GC-rich sequence motif. Star-PAP interacts with RNA harboring multiple binding motifs (E) Model of the nuclear phosphoinositide signaling-regulated Star-PAP control of BIK expression. Etoposide-induced DNA damage signal stimulates the nuclear localization of PKCd, which is then integrated into the Star-PAP complex and interacts with the PI4,5P 2 -producing enzyme PIPKIa. The active PIPKIa generates PI4,5P 2 to activate PKCd, which in turn promotes the activities of Star-PAP for the 3 0 end processing of the BIK mRNA.
that have a relatively large footprint on the UTR. Star-PAP binding to the pre-mRNA recruits CPSF160 and CPSF73 by direct protein-protein interactions . Unlike canonical PAPa, Star-PAP, CPSF160, and CPSF73 are sufficient to reconstitute specific 3 0 end cleavage in vitro, indicating that the CstF complex plays a less important role for Star-PAP targets . Thus, for some Star-PAP exclusive pre-mRNA targets a plausible explanation for loss of PAPa usage could be the loss of CPSFCstF complex assembly onto the target mRNAs, resulting in deficient recruitment of PAPa to the pre-mRNAs. Sequence analysis of Star-PAP-regulated genes, including BIK, has demonstrated that apart from the GC-rich sequence around the cleavage site, there is depletion of U-rich sequence in the region of DSE resulting in a suboptimal CstF recognition site ( Figure 6 ). The deficiency of CstF binding would impede both the stable assembly of CPSF-160 on the poly(A) signal and recruitment of PAPa to the cleavage site of BIK UTR. These changes could render BIK an exclusive Star-PAP target.
PKCd is a central switch that controls the apoptosis pathway, and this requires the nuclear localization and cleavage of PKCd by caspase-3 (Reyland, 2007 ). Yet, considerable evidence indicates that the full-length PKCd initiates the apoptotic response to DNA damage and acts upstream of caspase-3 (Cataldi et al., 2002; Fujii et al., 2000; Humphries et al., 2006) . Only the intact PKCd was detected associated with the Star-PAP complex, indicating that PKCd modulation of Star-PAP is an early event in the PKCd response to DNA damage.
In the nucleus, the regulation of PKCd by lipid messengers such as diacylglycerol (DAG) or phosphoinositides has not been defined. Our data supports a model where PKCd is recruited to the Star-PAP complex by direct interaction with PIPKIa, and this interaction blocked PKCd activity, but PI4,5P 2 generated by PIPKIa stimulated PKCd activity even in the presence of PIPKIa ( Figure 7E ). This regulatory mechanism for PKCd is unexpected, with the potential for utilization in other PIPKIa-and PKCd-regulated pathways. PKCd phosphorylates Star-PAP, and perhaps other components in the complex, to regulate BIK pre-mRNA 3 0 end processing. The data also demonstrate that DNA damage-induced PKCd activity is required for the priming of Star-PAP such that PI4,5P 2 generated by PIPKIa can stimulate Star-PAP poly(A) polymerase activity ( Figure 5C ).
PKCd can also be activated by DAG that is generated by nuclear phosphoinositide-phospholipase C toward PI4,5P 2 (Stahelin et al., 2004) . We showed that the DAG analog PMA stimulated PKCd phosphorylation of Star-PAP ( Figure 2E ). However, the PKCd phosphorylation of Star-PAP was blocked by PIPKIa binding and relieved by PI4,5P 2 but not PMA. This indicates that in vivo PI4,5P 2 and not DAG modulates PKCd in the Star-PAP pathway that controls BIK expression.
The 3 0 end processing of BIK requires a Star-PAP-dependent signaling nexus that contains at least two key signaling enzymes -PIPKIa, which generates PI4,5P 2 , and PKCd, which is regulated by direct binding of PIPKIa and PI4,5P 2 stimulation. BIK and HO-1 are exclusive Star-PAP target genes that are both regulated by PIPKIa and PI4,5P 2 , but the BIK expression pathway is in addition controlled by PKCd. This is the first indication that distinct signaling pathways that utilize different signaling enzymes regulate Star-PAP control of gene expression. The identification of PKCd as a component of this nexus integrates Star-PAP, PKCd, PIPKIa, and PI4,5P 2 into a signaling pathway essential for BIK expression and initiation of apoptosis, and therefore has wide ramifications for mRNA processing and gene expression.
EXPERIMENTAL PROCEDURES
Cell Lines, Transfection, and Treatments Human embryonic kidney (HEK) 293 cells were obtained from American Type Culture Collection (ATCC) and cultured in 13 DMEM supplemented with 10% fetal bovine serum and penicillin/streptomycin (50 U/ml) and were grown at 37 C in 5% CO 2 . Transfection with the plasmids and the siRNAs (Supplemental Information) was performed as described . Whenever required, cells were treated with 100 mM etoposide/tBHQ or the vehicle control, DMSO, for 4 hr or prolonged time as indicated and harvested for analysis.
Quantitative Real-Time RT-PCR Total RNA was extracted and reverse transcribed. Target mRNA was quantified with the MyiQ single-color real-time PCR detection system (Bio-Rad) as described previously . Single-product amplification was confirmed by melting-curve analysis, and primer efficiency was near 100% in all experiments. Target mRNA abundance was normalized to GAPDH expression. Primers used for mRNA expression and 3 0 end cleavage are shown in Supplemental Information.
Immunoblot, Immunoprecipitation, and Antibodies IB and IP were carried out as described . The intensity of the bands on images was quantified using ImageJ software. Input = 10% of the total protein used for the IP. The antibodies used are shown in Supplemental Information.
Protein Kinase Assay
The kinase assay was performed as detailed in the Supplemental Information.
Immunofluorescence Microscopy
This was performed as previously described (Boronenkov et al., 1998) . The ratios for comparing protein associations were generated by computerized counting of the overlaid yellow spots in 20 cells for each assay condition from a representative experiment.
GST Pull-Down Assay
Human recombinant GST-tagged PKCd (echelon, #E-K037) and His-tagged Star-PAP or PIPKIa (affinity purified) were subjected to GST pull-down assay as described previously . Input = 1% of the total protein used for the pull-down.
RNA Immunoprecipitation RIP was performed as described , using antibodies against endogenous RNA Pol II, Star-PAP, PAPa, PIPKIa, and PKCd. The primers used to detect the BIK or GCLC UTR are shown in Supplemental Information.
3 0 RACE and mRNA 3 0 End Cleavage Measurement 3 0 RACE was performed with the GeneRacer system (Invitrogen, #L1502-01)
using BIK or GAPDH gene-specific primers and the 3 0 adapter primer, following the manufacturer's instructions. PCR products were run on agarose gel, and individual DNA bands were excised, purified, and ligated into the pGEM-T Easy Vector (Promega, #A1360) for sequencing. For the 3 0 end cleavage, total RNA was isolated and the uncleaved pre-mRNA level was measured by real-time PCR, as described . The noncleaved message was represented as fold over the total mRNA and normalized against the nontreated control sample.
Poly(A) Polymerase Assay
The FLAG-tagged Star-PAP was affinity purified, and the poly(A) polymerase assay was carried out using the 45-mer RNA oligonucleotide (UAGGGA) 5 A 15 as an RNA substrate, as described previously .
RNA EMSA and RNase Footprinting
Uniformly radiolabeled BIK UTR RNA substrates were prepared by run-off in vitro transcription from the linearized plasmid pTZ-BIK (harbors T7 promoter and BIK 3 0 UTR) using the T7 transcription Kit (Fermentas). EMSA was carried out in 20 ml EMSA binding buffer, as described . The RNA Footprinting was carried out as detailed in the Supplemental Information.
Sequence Analysis of Star-PAP Target Gene UTRs
The microarray data for Star-PAP knockdown in HEK293 cells were analyzed. Cleavage site information was obtained from PolyA_DB . The Robust Multichip Average (RMA) method was used for data normalization, and the cutoff of p value < 0.05 (t test) and fold change > 1.5 was used to select genes showing significant downregulation, which were considered as Star-PAP targets. Those with one poly(A) signal only as based on the cDNA and EST evidence were used for nucleotide and ciselement analyses. The proportional test and the Fisher's exact test were used to assess the difference in nucleotide content and the significance of 4-mers in different regions surrounding cleavage sites, respectively.
DNA Laddering Assay
The assay was performed as described (Gong et al., 1994) . Equal amounts of cells from each experimental condition were collected 24 hr after etoposide treatment and fixed with ice-cold 70% ethanol. DNA was extracted using phosphate-citrate buffer, treated with RNase and proteinase K, and analyzed by agarose gel electrophoresis.
Detection of Caspase Activities
Caspase activities under the experimental conditions were measured using commercially available assay kits as described in the Supplemental Information. 
SUPPLEMENTAL INFORMATION
Supplemental Experimental Procedures
Plasmids and Constructs
The wild type and the polymerase-dead (D216/218A) Star-PAP as well as the wild type and the kinase dead (D322A) PIPKI mutant cDNAs were inserted into the pCMVTag4a (Stratagene) vector through EcoRI and SalI restriction sites. PKC wild type and kinase-dead plasmids were purchased from "Addgene (16386, 16389)". Silenceresistant mutations were generated in the Star-PAP, PIPKI, and PKC cDNAs to render it insensitive to the siRNA oligos.
Protein Kinase Assay
The kinase assay was carried out in 1X kinase buffer containing 4 mM MOPS pH 7. were then subjected to SDS-PAGE followed by phosphorimaging with a Storm 840 phosphorimager (Molecular Dynamics) and quantified using the ImageQuant 5.1 software (Molecular Dynamics). Quantification of the kinase activities was normalized to the substrate-only lane.
RNase Footprinting
The RNA Footprinting was carried out by probing the BIK UTR RNA fragment with RNase S or RNase T1 followed by the detection of the cleaved fragments by extension of a primer complementary to the 3'-end of BIK RNA as described (Damgaard et al., 
